Email this article 
Post a Comment 
Serum vascular cell adhesion molecule-1 (VCAM1) level is elevated in colorectal cancer regardless of the tumor stage
Abstract
Purpose: Vascular cell adhesion molecule-1 (VCAM1) is a transmembrane glycoprotein, which is expressed on endothelium and plays role in inflammation. It is over-expressed on colorectal cancer (CRC) cells and plays role in metastasis development and angiogenesis. We aimed to compare serum VCAM1 levels of CRC patients with heathy controls and evaluate its relationship with clinicopathological parameters, treatment response and overall survival (OS).
Methods: The study enrolled 111 patients with histopathologically confirmed CRC followed-up in our clinic and 30 sex- and age-matched healthy controls. Pre-treatment serum VCAM1 levels were determined by the solid-phase sandwich ELISA method.
Results: Metastatic disease was present in 57 patients. Forty percent of 40 metastatic patients receiving systemic therapy had partial or complete response. The median serum VCAM1 level was significantly higher in CRC patients than controls (p<0.001). In addition, serum VCAM1 level was significantly higher in diabetic CRC patients than those without diabetes (p = 0.03). There was no significant relationship between VCAM1 and other clinicopathological parameters including stage and response to systemic therapy. The median follow-up period was 12 (±8.2) months. Twenty patients were dead at the time of analysis. The presence of metastasis (p < 0.001) and elevated CEA level (p < 0.001) were factors affecting OS significantly. However, serum VCAM1 did not have a significant impact on OS (p = 0.55).
Conclusion: Serum VCAM1 level is significantly elevated in CRC patients regardless of the tumor stage. However, it has no prognostic or predictive role for response to systemic therapy.
Keywords
Full Text:
PDFReferences
Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal. 2011; 15(6):1607-38.
Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001; 37(18):2392-7.
Velikova G, Banks RE, Gearing A, et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer. 1998;77(11):1857-63.
Banner BF, Savas L, Woda BA. Expression of adhesion molecules in the host response to colon carcinoma. Ultrastruct Pathol. 1995; 19(2):113-8.
Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92(16):1329-36.
Piali L, Fichtel A, Terpe HJ, et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med. 1995;181(2):811-6.
Maurer CA, Friess H, Kretschmann B, et al. Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer. 1998; 79(1):76-81.
Suzuki Y, Ohtani H, Mizoi T, et al. Cell adhesion molecule expression by vascular endothelial cells as an immune/ inflammatory reaction in human colon carcinoma. Jpn J Cancer Res. 1995; 86(6):585-93.
Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995; 376(6540):517-9.
Markocka-Maczka K. Concentration of serum soluble forms of ICAM-1 (sVCAM-1) and VCAM-1 (sVCAM-1) in patients with chronic pancreatitis and in patients with pancreatic carcinoma. Wiad Lek. 2003;56(3-4):147-51.
Giannoulis K, Angouridaki C, Fountzilas G, et al. Serum concentrations of soluble ICAM-1 and VCAM-1 in patients with colorectal cancer. Clinical implications. Tech Coloproctol. 2004;8 Suppl 1:s65-7.
Velikova G, Banks RE, Gearing A, et al. Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer. 1997; 76(11):1398-404.
Holubec L Jr, Topolcan O, Finek J, et al. Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinoma. Anticancer Res. 2005; 25(3A):1597-601.
Tang JH, Zhao JH, Gong JP, et al. Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer. Zhonghua Zhong Liu Za Zhi. 2007; 29(3):210-4.
Coskun U, Sancak B, Sen I, et al. Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages. Int Immunopharmacol. 2006;6(4): 672-7.
Qiao XM, Wang ZM. Significance of concentration of serum soluble vascular cell adhesion molecule-1 in epithelial ovarian carcinoma. Ai Zheng. 2004;23(1):81-4.
Kawano T, Yanoma S, Nakamura Y, et al. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol. 2005; 26(5):308-13.
De Cicco C, Ravasi L, Zorzino L, et al. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer. Curr Cancer Drug Targets. 2008;8(3):199-206.
Christiansen I, Sundström C, Enblad G, Tötterman TH. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol. 1998;102(3):701-9.
Svobodova S, Topolcan O, Holubec L Jr, et al. Parameters of biological activity in colorectal cancer. Anticancer Res. 2011;31(1):373-8.
Liu Y, Starr MD, Bulusu A, et al. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med. 2013; 2(2):234-42.
Yamada Y, Arao T, Matsumoto K, et al. Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci. 2010;101(8):1886-90.
Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A, Kemona H. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res. 2012;129(4):e47-50.
Banks RE, Gearing AJ, Hemingway IK, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993;68(1):122-4.
Braun M, Pietsch P, Zepp A, et al. Regulation of Tumor Necrosis Factor-α and Interleukin-1β Induced Adhesion Molecule Expression in Human Vascular Smooth Muscle Cells by cAMP. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; 17: 2568-75.
DOI: http://dx.doi.org/10.14319/ijcto.42.5
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013